Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Metabolic Disorders Therapeutics Market by Product (Metachromatic Leukodystrophy, Globoid Leukodystrophy, Hepatic Encephalopathy, Others) and by Disease (Diabetes, Obesity, Hypercholesterolemia, Lysosomal Storage Diseases): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03212

Pages: NA

Charts: NA

Tables: NA

Metabolic disorders usually occur due to disruption of the normal processes of the body. These disorders can be hereditary or acquired and the symptoms differ from person to person. Some metabolic disorders cause mild symptoms that can be managed with slight medication and lifestyle changes, whereas few can cause life-threatening symptoms, such as breathing problems, seizure, and organ failure. The treatment for inherited metabolic disorders requires long-term nutritional supplementation and treatment, while those that are caused due to some other disease are treated after those conditions are cured.

The introduction of patient assistance programs to provide treatment for a range of metabolic disorders and the rise in awareness about the availability of therapeutics for these diseases drive the market growth. Moreover, the advancement in technology and increase in funding for the development of novel therapeutic approaches from government and non-government organizations are expected to further boost the market. Some of the commonly available treatment procedures for metabolic disorders include a range of therapeutic medications such as vitamin, mineral, physical therapy, and surgeries.

The global metabolic disorders therapeutics market is segmented based on product, disease, and region. Based on product, it is categorized into metachromatic leukodystrophy, globoid leukodystrophy, hepatic encephalopathy, and others. Based on application, it is divided into diabetes, obesity, hypercholesterolemia, and lysosomal storage diseases. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major players, such as AbbVie, Novo Nordisk, Actelion Pharmaceuticals, Sanofi, Biocon, Merck, Boehringer Ingelheim, AstraZeneca, CymaBay Therapeutics, and Eli Lilly and Company, are also provided in this report.

Key Benefits

  • This report provides an extensive analysis of the current and emerging market trends and dynamics  in the global metabolic disorders therapeutics market to identify the prevailing market opportunities.
  • The projections in this report are made by analyzing the current trends and future market potential in terms of value.
  • Competitive intelligence helps to understand the competitive scenario across the geographies.
  • An in-depth analysis of current research and clinical developments within market is provided with key dynamic factors that help understand the market behavior.

 Key Market Segments

  • By Product
    • Metachromatic Leukodystrophy
    • Globoid Leukodystrophy
    • Hepatic Encephalopathy
    • Others
  • By Disease
    • Diabetes
    • Obesity
    • Hypercholesterolemia
    • Lysosomal Storage Diseases
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Merck
  • AbbVie
  • Actelion Pharmaceuticals
  • Eli Lilly and Company
  • Novo Nordisk
  • Sanofi
  • Biocon
  • CymaBay Therapeutics
  • AstraZeneca
  • Boehringer Ingelheim

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: METABOLIC DISORDERS THERAPEUTICS MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Metachromatic Leukodystrophy

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Globoid Leukodystrophy

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Hepatic Encephalopathy

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Others

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: METABOLIC DISORDERS THERAPEUTICS MARKET, BY DISEASE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Disease

    • 5.2. Diabetes

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Obesity

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Hypercholesterolemia

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Lysosomal Storage Diseases

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: METABOLIC DISORDERS THERAPEUTICS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product

      • 6.2.3. Market Size and Forecast, By Disease

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Metabolic Disorders Therapeutics Market

        • 6.2.5.1. Market Size and Forecast, By Product
        • 6.2.5.2. Market Size and Forecast, By Disease

      • 6.2.6. Canada Metabolic Disorders Therapeutics Market

        • 6.2.6.1. Market Size and Forecast, By Product
        • 6.2.6.2. Market Size and Forecast, By Disease

      • 6.2.7. Mexico Metabolic Disorders Therapeutics Market

        • 6.2.7.1. Market Size and Forecast, By Product
        • 6.2.7.2. Market Size and Forecast, By Disease

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product

      • 6.3.3. Market Size and Forecast, By Disease

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Metabolic Disorders Therapeutics Market

        • 6.3.5.1. Market Size and Forecast, By Product
        • 6.3.5.2. Market Size and Forecast, By Disease

      • 6.3.6. Germany Metabolic Disorders Therapeutics Market

        • 6.3.6.1. Market Size and Forecast, By Product
        • 6.3.6.2. Market Size and Forecast, By Disease

      • 6.3.7. Italy Metabolic Disorders Therapeutics Market

        • 6.3.7.1. Market Size and Forecast, By Product
        • 6.3.7.2. Market Size and Forecast, By Disease

      • 6.3.8. Spain Metabolic Disorders Therapeutics Market

        • 6.3.8.1. Market Size and Forecast, By Product
        • 6.3.8.2. Market Size and Forecast, By Disease

      • 6.3.9. UK Metabolic Disorders Therapeutics Market

        • 6.3.9.1. Market Size and Forecast, By Product
        • 6.3.9.2. Market Size and Forecast, By Disease

      • 6.3.10. Russia Metabolic Disorders Therapeutics Market

        • 6.3.10.1. Market Size and Forecast, By Product
        • 6.3.10.2. Market Size and Forecast, By Disease

      • 6.3.11. Rest Of Europe Metabolic Disorders Therapeutics Market

        • 6.3.11.1. Market Size and Forecast, By Product
        • 6.3.11.2. Market Size and Forecast, By Disease

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product

      • 6.4.3. Market Size and Forecast, By Disease

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Metabolic Disorders Therapeutics Market

        • 6.4.5.1. Market Size and Forecast, By Product
        • 6.4.5.2. Market Size and Forecast, By Disease

      • 6.4.6. Japan Metabolic Disorders Therapeutics Market

        • 6.4.6.1. Market Size and Forecast, By Product
        • 6.4.6.2. Market Size and Forecast, By Disease

      • 6.4.7. India Metabolic Disorders Therapeutics Market

        • 6.4.7.1. Market Size and Forecast, By Product
        • 6.4.7.2. Market Size and Forecast, By Disease

      • 6.4.8. South Korea Metabolic Disorders Therapeutics Market

        • 6.4.8.1. Market Size and Forecast, By Product
        • 6.4.8.2. Market Size and Forecast, By Disease

      • 6.4.9. Australia Metabolic Disorders Therapeutics Market

        • 6.4.9.1. Market Size and Forecast, By Product
        • 6.4.9.2. Market Size and Forecast, By Disease

      • 6.4.10. Thailand Metabolic Disorders Therapeutics Market

        • 6.4.10.1. Market Size and Forecast, By Product
        • 6.4.10.2. Market Size and Forecast, By Disease

      • 6.4.11. Malaysia Metabolic Disorders Therapeutics Market

        • 6.4.11.1. Market Size and Forecast, By Product
        • 6.4.11.2. Market Size and Forecast, By Disease

      • 6.4.12. Indonesia Metabolic Disorders Therapeutics Market

        • 6.4.12.1. Market Size and Forecast, By Product
        • 6.4.12.2. Market Size and Forecast, By Disease

      • 6.4.13. Rest of Asia Pacific Metabolic Disorders Therapeutics Market

        • 6.4.13.1. Market Size and Forecast, By Product
        • 6.4.13.2. Market Size and Forecast, By Disease

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product

      • 6.5.3. Market Size and Forecast, By Disease

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Metabolic Disorders Therapeutics Market

        • 6.5.5.1. Market Size and Forecast, By Product
        • 6.5.5.2. Market Size and Forecast, By Disease

      • 6.5.6. South Africa Metabolic Disorders Therapeutics Market

        • 6.5.6.1. Market Size and Forecast, By Product
        • 6.5.6.2. Market Size and Forecast, By Disease

      • 6.5.7. Saudi Arabia Metabolic Disorders Therapeutics Market

        • 6.5.7.1. Market Size and Forecast, By Product
        • 6.5.7.2. Market Size and Forecast, By Disease

      • 6.5.8. UAE Metabolic Disorders Therapeutics Market

        • 6.5.8.1. Market Size and Forecast, By Product
        • 6.5.8.2. Market Size and Forecast, By Disease

      • 6.5.9. Argentina Metabolic Disorders Therapeutics Market

        • 6.5.9.1. Market Size and Forecast, By Product
        • 6.5.9.2. Market Size and Forecast, By Disease

      • 6.5.10. Rest of LAMEA Metabolic Disorders Therapeutics Market

        • 6.5.10.1. Market Size and Forecast, By Product
        • 6.5.10.2. Market Size and Forecast, By Disease

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. AbbVie

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Novo Nordisk

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Actelion Pharmaceuticals

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Sanofi

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Biocon

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Merck

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Boehringer Ingelheim

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. AstraZeneca

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. CymaBay Therapeutics

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Eli Lilly And Company

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET FOR METACHROMATIC LEUKODYSTROPHY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET FOR GLOBOID LEUKODYSTROPHY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET FOR HEPATIC ENCEPHALOPATHY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET FOR DIABETES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET FOR OBESITY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET FOR HYPERCHOLESTEROLEMIA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET FOR LYSOSOMAL STORAGE DISEASES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 15. U.S. METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 16. U.S. METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 17. CANADA METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 18. CANADA METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 19. MEXICO METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 20. MEXICO METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE METABOLIC DISORDERS THERAPEUTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 23. EUROPE METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 24. FRANCE METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 25. FRANCE METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 26. GERMANY METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 27. GERMANY METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 28. ITALY METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 29. ITALY METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 30. SPAIN METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 31. SPAIN METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 32. UK METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 33. UK METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 34. RUSSIA METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 35. RUSSIA METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 36. REST OF EUROPE METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 37. REST OF EUROPE METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 40. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 41. CHINA METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 42. CHINA METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 43. JAPAN METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 44. JAPAN METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 45. INDIA METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 46. INDIA METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 47. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 48. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 49. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 50. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 51. THAILAND METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 52. THAILAND METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 53. MALAYSIA METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 54. MALAYSIA METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 55. INDONESIA METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 56. INDONESIA METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA METABOLIC DISORDERS THERAPEUTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 61. LAMEA METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 62. BRAZIL METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 63. BRAZIL METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 66. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 67. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 68. UAE METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 69. UAE METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 70. ARGENTINA METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 71. ARGENTINA METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 72. REST OF LAMEA METABOLIC DISORDERS THERAPEUTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 73. REST OF LAMEA METABOLIC DISORDERS THERAPEUTICS, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 74. ABBVIE: KEY EXECUTIVES
  • TABLE 75. ABBVIE: COMPANY SNAPSHOT
  • TABLE 76. ABBVIE: OPERATING SEGMENTS
  • TABLE 77. ABBVIE: PRODUCT PORTFOLIO
  • TABLE 78. ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 79. NOVO NORDISK: KEY EXECUTIVES
  • TABLE 80. NOVO NORDISK: COMPANY SNAPSHOT
  • TABLE 81. NOVO NORDISK: OPERATING SEGMENTS
  • TABLE 82. NOVO NORDISK: PRODUCT PORTFOLIO
  • TABLE 83. NOVO NORDISK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. ACTELION PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 85. ACTELION PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 86. ACTELION PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 87. ACTELION PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 88. ACTELION PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. SANOFI: KEY EXECUTIVES
  • TABLE 90. SANOFI: COMPANY SNAPSHOT
  • TABLE 91. SANOFI: OPERATING SEGMENTS
  • TABLE 92. SANOFI: PRODUCT PORTFOLIO
  • TABLE 93. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94. BIOCON: KEY EXECUTIVES
  • TABLE 95. BIOCON: COMPANY SNAPSHOT
  • TABLE 96. BIOCON: OPERATING SEGMENTS
  • TABLE 97. BIOCON: PRODUCT PORTFOLIO
  • TABLE 98. BIOCON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99. MERCK: KEY EXECUTIVES
  • TABLE 100. MERCK: COMPANY SNAPSHOT
  • TABLE 101. MERCK: OPERATING SEGMENTS
  • TABLE 102. MERCK: PRODUCT PORTFOLIO
  • TABLE 103. MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104. BOEHRINGER INGELHEIM: KEY EXECUTIVES
  • TABLE 105. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 106. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
  • TABLE 107. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
  • TABLE 108. BOEHRINGER INGELHEIM: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 110. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 111. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 112. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 113. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. CYMABAY THERAPEUTICS: KEY EXECUTIVES
  • TABLE 115. CYMABAY THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 116. CYMABAY THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 117. CYMABAY THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 118. CYMABAY THERAPEUTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 120. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 121. ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 122. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 123. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET
  • FIGURE 3. SEGMENTATION METABOLIC DISORDERS THERAPEUTICS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN METABOLIC DISORDERS THERAPEUTICS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALMETABOLIC DISORDERS THERAPEUTICS MARKET
  • FIGURE 11. METABOLIC DISORDERS THERAPEUTICS MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. METABOLIC DISORDERS THERAPEUTICS MARKET FOR METACHROMATIC LEUKODYSTROPHY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. METABOLIC DISORDERS THERAPEUTICS MARKET FOR GLOBOID LEUKODYSTROPHY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. METABOLIC DISORDERS THERAPEUTICS MARKET FOR HEPATIC ENCEPHALOPATHY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. METABOLIC DISORDERS THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. METABOLIC DISORDERS THERAPEUTICS MARKET SEGMENTATION, BY BY DISEASE
  • FIGURE 17. METABOLIC DISORDERS THERAPEUTICS MARKET FOR DIABETES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. METABOLIC DISORDERS THERAPEUTICS MARKET FOR OBESITY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. METABOLIC DISORDERS THERAPEUTICS MARKET FOR HYPERCHOLESTEROLEMIA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. METABOLIC DISORDERS THERAPEUTICS MARKET FOR LYSOSOMAL STORAGE DISEASES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 25. COMPETITIVE DASHBOARD
  • FIGURE 26. COMPETITIVE HEATMAP: METABOLIC DISORDERS THERAPEUTICS MARKET
  • FIGURE 27. TOP PLAYER POSITIONING, 2024
  • FIGURE 28. ABBVIE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. ABBVIE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. ABBVIE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. NOVO NORDISK: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. NOVO NORDISK: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. NOVO NORDISK: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. ACTELION PHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. ACTELION PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. ACTELION PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. SANOFI: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. SANOFI: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. SANOFI: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. BIOCON: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. BIOCON: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. BIOCON: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. MERCK: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. MERCK: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. MERCK: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. BOEHRINGER INGELHEIM: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. ASTRAZENECA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. ASTRAZENECA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. CYMABAY THERAPEUTICS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. CYMABAY THERAPEUTICS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. CYMABAY THERAPEUTICS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. ELI LILLY AND COMPANY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Metabolic Disorders Therapeutics Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved